Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and...
Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50. The parent company would retain more than 1.
Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50. The parent company would retain more than 1.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPOJ&J said it launched a roadshow for Kenvue's IPO of more than 151 million shares of common stock.
Leer más »
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report saysJ&J's consumer health unit Kenvue aims to raise $3.5 billion or more in the initial public offering, sources told the Wall Street Journal.
Leer más »
WSJ News Exclusive | J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue MarketJohnson & Johnson is set to begin pitching shares of its consumer-healthcare business in a big test for the IPO market
Leer más »
Breakingviews - J&J carves itself up at a discountJohnson & Johnson is paying a price to dismember itself. The $422 billion healthcare giant is floating part of its consumer business, named Kenvue, which sells brands ranging from Listerine to Tylenol. It’s hoping to raise $3.5 billion or more, at a valuation of around $40 billion, according to the Wall Street Journal. That’s nearly a 20% discount to rival Haleon , the consumer business spun off from GSK last year.
Leer más »
Boris Johnson Tried to Meet With Queen While Sick With COVID SymptomsAfter the meeting was switched to the phone, the queen told an aide “she couldn’t hear a word of what Johnson had said, he was coughing so much.”
Leer más »